A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis
Kristine L. Stump(Teva Pharmaceuticals (United States)), Matthew M. Seavey(Brandywine Photonics (United States))
Cited by 76
Related Papers
Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105
|Cancer Immunology Immunotherapy|2011|69
Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors
|Immunologic Research|2008|62
The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy
|Cancer Immunology Immunotherapy|2011|54
ISG15 as a Novel Target for Tumor Immunotherapy (95.13)
|The Journal of Immunology|2010|1